Synergistic inhibitory effect of high-intensity focused ultrasound combined with chemotherapy on Dunning adenocarcinoma

BJU International

Volumn 95, Issue 6, 2005, Pages 881-885

  Paparel, Philippe ^a   Curiel, Laura ^b   Chesnais, Sabrina ^b   Ecochard, Rene ^b   Chapelon, Jean Yves ^b   Gelet, Albert ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

Dunning model; Estramustine phosphate; HIFU; Paclitaxel; Prostate cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARMUSTINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRAMUSTINE PHOSPHATE; MITOXANTRONE; PACLITAXEL; PREDNISOLONE; PROSTATE SPECIFIC ANTIGEN; TAXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER GROWTH; CANCER STAGING; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; HIGH RISK POPULATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; RAT; TREATMENT OUTCOME; TUMOR VOLUME; ULTRASOUND THERAPY;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; ESTRAMUSTINE; MALE; PACLITAXEL; PROSTATIC NEOPLASMS; RATS; ULTRASOUND, HIGH-INTENSITY FOCUSED, TRANSRECTAL;

EID: 17444427064     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2005.05420.x     Document Type: Conference Paper

References (28)

1. Aleman M, Karakiewicz PI, Kupelian P et al. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening. Urology 2003; 62: 70-4
2. Shipley WU, Thames HD, Sandler HM et al. Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999; 281: 1598-604
3. Gelet A, Chapelon JY, Bouvier R, Rouviere O, Lyonnet D, Dubernard JM. Transrectal high intensity focused ultrasound: factors influencing the out come. Eur Urol 2001; 40: 124-9
4. Zietman AL, Prince EA, Nakfoor BM, Park JJ. Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system. Int J Radiat Oncol Biol Phys 1997; 38: 1067-70
5. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
6. Klotz LH, Goldenberg SL, Jewett MA et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791-4
7. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
8. Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. Urology 1999; 54 (Suppl. 6A): 30-5
9. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol 2001; 19: 2509-16
10. Prat F, Chapelon JY, El Fadil FA, Theillere Y, Ponchon T, Cathignol D. In vivo effects of cavitation alone or in combination with chemotherapy in a peritoneal carcinomatosis in the rat. Br J Cancer 1993; 68: 13-7
11. Moore WE, Lopez RM, Matthews DE. Evaluation of high-intensity therapeutic ultrasound irradiation in the treatment of experimental hepatoma. J Pediatr Surg 1989; 24: 30-3
12. Yang R, Reilly CR, Rescorla FJ et al. Effects of high intensity focused ultrasound in the treatment of experimental neuroblastoma. J Pediatr Surg 1992; 27: 246-50
13. Yang R, Reilly CR, Rescorla FJ et al. High-intensity focused ultrasound in the treatment of experimental liver cancer. Arch Surg 1991; 126: 1002-9
14. Fry FJ, Johnson LK. Tumor irradiation with intense ultrasound. Ultrasound Med Biol 1978; 4: 337-41
15. Haas N, Roth B, Garay C et al. Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology 2001; 58: 59-64
16. Chavrier F, Chapelon JY, Gelet A, Cathignol D. Modeling of high-intensity focused ultrasound-induced lesions in the presence of cavitation bubbles. J Acoust Soc Am 2000; 108: 432-40
17. Lokeshwar L, Ferell SM, Block NL. Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy. Anticancer Res 1995; 15: 93-8
18. Chapelon JY, Margonari J, Vernier F, Gorry F, Ecochard R, Gelet A. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 1992; 52: 6353-7
19. Sapareto SA, Dewey WC. Thermal dose determination in cancer therapy. Int J Radiat Oncol Biol Phys 1984; 10: 787-800
20. Fry WJ, Tucker D, Fry FJ, Wulff VJ. Physical factors involved in ultrasonically induced changes in living systems. II. Amplitude duration relations and the effect of hydrostatic pressure for nerve tissue. In Dunn F, O'Brien WD. Ultrasonic Biophysics. Stroudsburg: Dowden, Hutchinson & Ross, Inc, 1976: 249-58
21. Gelet A, Chapelon JY, Bouvier R et al. Transrectal high-intensity focused ultrasound, minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14: 519-28
22. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y. Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999; 161: 156-62
23. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004; 63: 297-300
24. Saad A, Hahn GM. Ultrasound enhanced drug toxicity on Chinese hamster ovary cells in vitro. Cancer Res 1989; 49: 5931-4
25. Yumita N, Umemura S. Sonodynamic antitumour effect of chloroaluminum phthalocyanine tetrasulfonate on murine solid tumour. J Pharm Pharmacol 2004; 56: 85-90
26. Yu T, Huang X, Hu K, Bai J, Wang Z. Treatment of transplanted adriamycin-resistant ovarian cancers in mice by combination of adriamycin and ultrasound exposure. Ultrason Sonochem 2004; 11: 287-91
27. Oudard S, Legrier ME, Boye K et al. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol 2003; 169: 1729-34
28. Konety BR, Eastham JA, Reuter VE et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004; 171: 709-13